Morselized foam for wound treatment

• US 20090004271A1
• Filed: 06/29/2007
• Published: 01/01/2009
• Est. Priority Date: 06/29/2007
• Status: Abandoned Application

• Current Assignee: Advanced Technologies and Regenerative Medicine, LLC (Johnson & Johnson)
• Original Assignee: Advanced Technologies and Regenerative Medicine, LLC (Johnson & Johnson)
• Inventors: Panozzo, Mary F., Brown, Laura J.
• Application Number:
  US11/824,086
• Publication Number:
  US 20090004271A1
• Time in Patent Office: Days
• US Class Current: 424/486
• CPC Class Codes: A61L 15/26 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof A61L15/225 takes precedence
• CPC Class Codes: A61L 15/425 Porous materials, e.g. foams or sponges
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C08L 67/04 Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence

Abstract

A wound treatment material comprising morselized foam is described. The morselized foam comprises a biocompatible, biodegradeable polymer. Methods for wound treatment and/or repair and/or regeneration of tissue using morselized foam are disclosed.

Claims

1. A morselized foam treatment of a wound, the morselized foam comprising biocompatible, biodegradable polymer wherein granulation tissue overgrowth of the morselized foam at about 7 days of contact with the wound is greater than the amount of granulation tissue overgrowth for an identical non-morselized foam.

2. The morselized foam of claim 1 wherein the biocompatible, biodegradeable polymer is selected from the group consisting of aliphatic polyesters, poly(amino acids), copoly(ether-esters), polyalkylene oxalates, polyamides, poly(iminocarbonates), polyorthoesters, polyoxaesters, polyamidoesters, polyoxaesters containing amine groups, poly(anhydrides), polyphosphazenes, and combinations thereof.

3. The morselized foam of claim 2 wherein the aliphatic polyester is homopolymers and copolymers of monomers selected from the group consisting of lactide, glycolide, epsilon-caprolactone, p-dioxanone, trimethylene carbonate and combinations thereof.

4. The morselized foam of claim 2 wherein the aliphatic polyester is an elastomeric copolymer selected from the group consisting of poly(epsilon-caprolactone-co-glycolide), poly(epsilon-caprolactone-co-lactide), poly(p-dioxanone-co-lactide;

poly(epsilon-caprolactone-co-p-dioxanone);

poly(p-dioxanone-co-trimethylene carbonate);

poly(trimethylene carbonate-co-glycolide);

poly(trimethylene carbonate-co-lactide) and combinations thereof.

5. The morselized foam of claim 4 wherein the elastomeric copolymer is poly(epsilon-caprolactone-co-glycolide) having a mole ratio of epsilon-caprolactone to glycolide of from about 30/70 to about 70/30.

6. The morselized foam of claim 4 wherein the elastomeric copolymer is poly(epsilon-caprolactone-co-glycolide) having a mole ratio of epsilon-caprolactone to glycolide of from about 35/65 to about 65/35.

7. The morselized foam of claim 4 wherein the elastomeric copolymer is poly(epsilon-caprolactone-co-glycolide) having a mole ratio of epsilon-caprolactone to glycolide of 35/65.

8. The morselized foam of claim 1 wherein the foam has a porosity of greater than 90 percent by volume

9. The morselized foam of claim 1 wherein the foam has a thickness of about 0.25 mm to about 0.75 mm.

10. The morselized foam of claim 1 wherein the foam has a width of about 1 mm to about 4 mm and a length of about 1 mm to about 4 mm.

11. The morselized foam of claim 1 wherein the foam has a porosity of greater than 90 percent by volume, a thickness of about 0.25 mm to about 0.75 mm, a width of about 1 mm to about 4 mm and a length of about 1 mm to about 4 mm.

12. The morselized foam of claim 1, wherein the average piece of morselized foam occupies about 0.1% to about 5% of the total wound volume.

14. The morselized foam of claim 1, further comprising one or more agents capable of stimulating or enhancing the attachment, proliferation or differentiation of tissue, the one or more agents being impregnated, encapsulated and/or coated thereon and/or therein.

15. The morselized foam of claim 14, wherein the one or more agents are selected from:

(i) anti-infectives, hormones, analgesics, anti-inflammatory agents, growth factors, chemotherapeutic agents, anti-rejection agents, prostaglandins, RGD peptides;

(ii) postpartum cells derived from umbilical cord tissue, postpartum cells derived from placental tissue, or their cell products or derivatives; and

(iii) myocytes, adipocytes, fibromyoblasts, ectodermal cell, muscle cells, osteoblast, chondrocyte, endothelial cells, fibroblast, pancreatic cells, hepatocyte, bile duct cells, bone marrow cells, neural cells, genitourinary cells, pluripotent cells, stem cells, precursor cells, or their cell products or derivatives thereof.

13. A morselized foam comprising a biocompatible, biodegradable elastomeric copolymer of poly(epsilon-caprolactone-co-glycolide), the copolymer having a mole ratio of epsilon-caprolactone to glycolide of 35/65;

wherein the morselized foam has a porosity of greater than 90 percent by volume, a thickness of about 0.25 mm to about 0.75 mm, a width of about 1 mm to about 4 mm, and a length of about 1 mm to about 4 mm.

16. A method of tissue repair and/or regeneration, the method comprising:

contacting a wound of a subject with morselized foam comprising biocompatible, biodegradable polymer wherein granulation tissue overgrowth of the morselized foam at about 7 days of contact with the wound is greater than the amount of granulation tissue overgrowth for an identical non-morselized foam.

17. The method of claim 16, wherein the morselized foam comprises a porosity of greater than 90 percent by volume, a thickness of about 0.25 mm to about 0.75 mm, a length of about 1 mm to about 4 mm, and a width of about 1 mm to about 4 mm.

18. The method of claim 17, wherein further comprising one or more agents capable of stimulating or enhancing the attachment, proliferation or differentiation of tissue, the one or more agents being impregnated, encapsulated and/or coated thereon and/or therein.

19. The method of claim 18, wherein the one or more agents are selected from:

(i) anti-infectives, hormones, analgesics, anti-inflammatory agents, growth factors, chemotherapeutic agents, anti-rejection agents, prostaglandins, RGD peptides;

(ii) postpartum cells derived from umbilical cord tissue, postpartum cells derived from placental tissue, or their cell products or derivatives; and

(iii) myocytes, adipocytes, fibromyoblasts, ectodermal cell, muscle cells, osteoblast, chondrocyte, endothelial cells, fibroblast, pancreatic cells, hepatocyte, bile duct cells, bone marrow cells, neural cells, genitourinary cells, pluripotent cells, stem cells, precursor cells, or their cell products or derivatives thereof.

20. The method of claim 16, wherein the average piece of morselized foam occupies about 0.1% to about 5% of the total wound volume.